Size Genetics: How Genes Influence Body Growth

Human height is roughly 80 percent heritable, meaning the bulk of the variation you see between people traces back to DNA rather than diet or lifestyle. But that figure masks an extraordinarily complicated genetic architecture: hundreds of common gene variants each nudge stature by a fraction of a centimeter, while a handful of rare mutations can shift it by tens of centimeters. The interplay between these genetic signals, the hormones they control, and the environmental conditions a person grows up in makes body growth one of the most richly studied traits in modern genetics.

The Growth Plate Is Where Genetic Instructions Become Bone

Almost all lengthening of the skeleton happens inside a thin strip of cartilage near the ends of long bones, called the growth plate. Cells there go through a tightly choreographed sequence: they start out small and inactive, then flatten and multiply, and finally enlarge before being replaced by bone tissue. That choreography is controlled by an overlapping set of signaling pathways, including Indian hedgehog, fibroblast growth factor (FGF), bone morphogenetic protein (BMP), Wnt, and TGF-beta, each of which has been validated in computational models and knockout experiments.¹ As these cells transition through their stages, their gene-expression profiles shift dramatically, and the pace of that transition determines how much new bone is deposited before the growth plate eventually fuses shut.²

Disruptions to any of these pathways can alter how quickly or slowly children grow. FGF receptor 3 (FGFR3) mutations, for example, cause achondroplasia, the most common form of disproportionate short stature. Collagen gene mutations also play a significant role: in one study of short-stature patients with skeletal abnormalities, about a quarter carried pathogenic variants in collagen genes, with COL2A1 mutations alone accounting for more than half of those cases.³ These single-gene disruptions illustrate how growth-plate biology sits at the mercy of its genetic instructions.

The Growth Hormone–IGF-1 Axis

If the growth plate is the engine, the growth hormone (GH)–IGF-1 pathway is the fuel line. The pituitary gland releases GH, which signals the liver and other tissues to produce insulin-like growth factor 1 (IGF-1). IGF-1 then travels to the growth plate and stimulates those cartilage cells to multiply. Genetic defects anywhere along this chain present with growth failure as their principal clinical feature, ranging from severe to mild short stature depending on where the disruption falls.⁴

How sensitively your body responds to GH is itself partly genetic and partly epigenetic. One study found that a common variant in the GH receptor gene accounted for about 19 percent of the variation in IGF-1 response, while chemical modifications (methylation) of the IGF-1 gene’s promoter region contributed about 30 percent. Together, those two factors explained roughly 43 percent of individual differences in GH sensitivity.⁵ That means even if two children have identical GH levels, their bodies may translate those signals into growth at very different rates because of variation in receptor genetics and gene regulation.

Beyond the DNA Sequence: Epigenetics and Early Nutrition

Your genes set the blueprint, but epigenetic marks, chemical tags on DNA that dial gene activity up or down without changing the underlying sequence, help determine whether that blueprint is fully realized. Nutrition during pregnancy and infancy is one of the strongest environmental forces that shapes these marks. Maternal nutrition around conception can produce long-term, potentially permanent changes in offspring DNA methylation patterns.⁶

Nutrition during breastfeeding also programs the GH–IGF-1 axis itself. Research suggests two distinct waves of programming: structural adaptations in the early postnatal period, where IGF-1 directly stimulates the growth of GH-releasing neurons in the brain, followed by permanent epigenetic changes that lock in the axis’s set point for adulthood.⁷ Body size, nutrition, and socioeconomic conditions in early life have all been linked to epigenomic changes, offering one mechanism through which poverty and food insecurity can literally get under the skin and alter growth trajectories.⁸

Genomic Imprinting and the Tug-of-War Before Birth

Not all genes are treated equally depending on which parent they come from. More than 100 “imprinted” genes are expressed from only the maternal or paternal copy, and many of them directly modulate fetal growth. The classic example is IGF-2, a powerful fetal growth factor expressed from the father’s copy, and its inhibitor, the IGF-2 receptor, expressed from the mother’s copy.⁹ Evolutionary biologists interpret this as a genetic tug-of-war: paternal genes push the fetus to extract more resources from the mother, while maternal genes push back to preserve the mother’s health for future pregnancies. Imprinted genes also shape the placenta, regulate organogenesis, and signal nutritional status between mother and fetus.

A large genome-wide study of birth weight in over 86,000 women found that most of the genetic loci influencing birth weight acted through the mother’s genotype, affecting the uterine environment. The notable exception was HMGA2, where the association was driven by the fetal genotype itself, meaning the baby’s own DNA at that locus directly influenced its size at birth.¹⁰

Why Males Are Taller

The average height gap between men and women is about 13 centimeters worldwide. Hormones, particularly testosterone’s effects on growth-plate activity during puberty, have long been considered the main driver. But a recent analysis of over 928,000 individuals, including more than 1,200 people with sex chromosome aneuploidies (atypical numbers of X or Y chromosomes), found that chromosomal dosage itself plays a substantial role. Each additional Y chromosome adds roughly 3.1 centimeters more to height than an additional inactive X chromosome, independent of hormones. That difference alone explains about 23 percent of the average height gap between typical males and females.¹¹

A key gene in this story is SHOX, which sits in a region shared by the X and Y chromosomes. SHOX promotes growth-plate cartilage cell proliferation. On the inactive X chromosome in females, SHOX expression is reduced compared to the active X, resulting in a net deficit. Deletions or mutations in the non-coding regulatory regions far downstream of SHOX have been linked to short stature in patients, indicating that the gene’s extensive control region, spanning hundreds of kilobases, is itself a vulnerable target.¹² Sex-specific epigenetic regulation of SHOX has also been linked to the relatively shorter stature of females.¹³

Not Just How Tall, but What Shape

Height is a single number, but bodies are three-dimensional. Genes do not uniformly scale up or down. Some variants primarily lengthen legs while others disproportionately grow the spine or head. A genome-wide analysis found that 130 of 670 known height-associated variants also significantly altered the sitting-height ratio, which captures how body proportions differ from one person to the next. Of those 130 variants, 71 acted disproportionately on leg length, while 59 acted more on the spine and head.¹⁴ This means two people of identical overall height can differ meaningfully in limb-to-torso ratio purely because of which height variants they carry. It also explains why certain populations with similar average heights can look quite different in build: the mix of leg-lengthening versus spine-lengthening variants varies across groups.

What Dogs and Horses Teach Us About Size Genetics

Domestic animals have undergone dramatic, rapid size diversification under human-directed breeding, and they offer unusually clean natural experiments in size genetics. In dogs, a single variant near the IGF-1 gene is found in virtually all small breeds and is nearly absent from giant breeds, making it one of the most powerful size-determining alleles known in any mammal.¹⁵ Among the very tiniest breeds, an additional mutation in the IGF-1 receptor itself further reduces body size; nine of thirteen tiny breeds carry it.¹⁶

More recently, researchers traced the small-size variant to an ancestral allele in a long non-coding RNA called IGF1-AS that was common in small wild canids before dogs were ever domesticated. This allele nearly vanished in Pleistocene wolves but was resurrected, essentially, by human selection for small breed dogs.¹⁷ The lesson is that major body-size variation can hinge on surprisingly few genetic changes when selection pressure is strong enough.

Horses tell a similar story. Just four genetic loci explain about 83 percent of size variation across horse breeds, and three of those loci contain genes (LCORL, HMGA2, and ZFAT) that also influence human height.¹⁸ HMGA2 in particular keeps showing up across species: it is associated with dog size, horse size, sheep body dimensions, and human height.¹⁹ Domestication seems to repeatedly exploit the same narrow set of genetic levers to generate extreme size diversity quickly.

Natural Selection Still Shapes Height

Height-associated gene variants show higher genetic differentiation across human populations than you would expect by chance, a statistical signature of natural selection acting on height in different environments.²⁰ The classic case study is the Netherlands. Dutch people are among the tallest in the world, and that is not just good nutrition. An analysis spanning three decades found that taller men consistently had more children, and taller women experienced higher child survival, meaning natural selection was actively favoring tall stature alongside the well-documented improvements in diet and healthcare.²¹

Selection does not always push in the same direction, though. In some populations, stabilizing selection favors average-height women, while in others, directional selection favors taller individuals. The point is that height is not a static trait merely inherited: it is actively evolving in many human populations, shaped by both survival advantages and mate preferences that differ from place to place.

Ancient DNA and the Shrinking Neolithic Farmers

One of the more striking findings from paleogenomics is that the transition to farming in Europe came with a drop in stature that genetics alone cannot explain. When researchers compared the polygenic height scores predicted from ancient DNA with actual skeletal measurements from the same individuals, Neolithic farmers were shorter than expected, about 3.8 centimeters shorter than predicted relative to earlier hunter-gatherers.²² That gap strongly suggests that environmental factors, likely poorer nutrition, higher disease burden, or both, were suppressing growth below genetic potential during the early farming period. Stature then steadily recovered across the Copper, Bronze, and Iron Ages as farming communities stabilized.

A complementary study of over 1,000 ancient individuals confirmed that the observed decrease in height between the Early Upper Paleolithic and the Mesolithic was qualitatively predicted by genetics, and that both skeletal and genetic height remained roughly constant between the Mesolithic and Neolithic before increasing into the Bronze Age.²³ Taken together, these studies show that genes set the ceiling, but environment determines how close a population gets to it. The Neolithic height dip is the clearest historical example of that gap.

Predicting Height From a Genome

With hundreds of height-associated variants now catalogued, researchers have built polygenic scores that aggregate their effects into a single number for each person. In one large cohort of children, a polygenic score combined with sex explained about 71 percent of adult height variation, nearly matching the 73 percent explained by the old-fashioned method of averaging the parents’ heights.²⁴ The prediction error was roughly 5 centimeters, which sounds imprecise for an individual but is clinically useful for flagging children who are genetically predisposed to fall well below average.

These scores also help clinicians distinguish between types of short stature. Among children diagnosed with “idiopathic” short stature, meaning no obvious cause had been found, those without a family history of shortness had polygenic score predictions significantly lower than what mid-parental height predicted. In other words, their DNA carried a measurable burden of height-reducing variants that was not apparent from their parents’ heights alone.²⁵ This kind of finding could eventually change how pediatric endocrinologists evaluate and treat children who are growing slowly.

Catch-Up Growth and Its Limits

When a child’s growth is temporarily suppressed by illness, malnutrition, or hormonal disruption, the body often compensates afterward with a burst of faster-than-normal growth. This catch-up growth appears to work because growth-inhibiting conditions delay the biological clock that normally slows and eventually stops growth. When the inhibition is removed, tissues retain more proliferative capacity than usual for the child’s age and grow faster to close the gap.²⁶

Catch-up growth has limits, though, and those limits can themselves be genetically mediated. In animal models, caloric restriction during pregnancy not only stunted offspring but caused catch-up growth failure in subsequent generations, driven by increased expression of a specific microRNA (miR-322) that suppressed growth hormone receptor levels in the liver.²⁷ This is a sobering example of how nutritional deprivation can reprogram growth regulation across generations through epigenetic and RNA-mediated mechanisms, effectively baking short stature into the biology of descendants who themselves have adequate food.

Targeted Therapies for Genetic Growth Conditions

For most people, the genetic hand they are dealt for height is simply the hand they play. But for children with specific single-gene growth disorders, targeted therapies are beginning to change the picture. The most prominent example is vosoritide, the first drug designed to counteract the molecular cause of achondroplasia. The FGFR3 mutation in achondroplasia puts a brake on growth-plate cartilage cell activity. Vosoritide works by binding to a receptor on those cartilage cells and triggering an intracellular signal that inhibits the overactive FGFR3 pathway, restoring more normal cartilage-to-bone conversion.²⁸

In clinical trials, children receiving vosoritide showed a sustained increase in growth speed at effective doses for up to 42 months.²⁹ A meta-analysis of trials testing vosoritide and a related drug, navepegritide, found that treated children grew about 1.4 centimeters per year faster than those on placebo, with the benefit more pronounced in children aged five and older.³⁰ That may sound modest, but compounded over years of childhood growth it translates into meaningful gains in adult height. These therapies represent a proof of concept: if you understand the genetic mechanism precisely enough, you can design a molecule to push back against it.

The Height–Cancer Connection

There is a well-established statistical link between greater adult height and slightly higher overall cancer risk, and it has a genetic basis worth understanding. The prevailing explanation is straightforward: taller people have more cells, and more cells means more opportunities for one of them to acquire a cancer-causing mutation. Height is influenced by many of the same growth-signaling pathways that, when dysregulated, contribute to cancer, including FGF, Wnt, and mTOR signaling.³¹ Melanoma in particular shows a stronger-than-expected relationship with height, which may reflect not just cell number but an increased rate of cell division mediated through higher IGF-1 levels in taller individuals.³²

This does not mean being tall is unhealthy in any practical sense. The absolute increase in cancer risk per centimeter of height is tiny, and it is dwarfed by lifestyle factors. But the association is a reminder that genes shaping growth do not operate in isolation: the same pathways that build a larger body can, in rare cases, contribute to its vulnerability. Growth is a balance, and evolution has navigated that balance for millions of years.

MicroRNAs and the Body’s Internal Clock

Beyond the well-known hormone pathways, smaller regulatory molecules called microRNAs help time how long the body keeps growing and in what proportions. The Lin28/let-7 pathway, originally discovered as a developmental timing mechanism in invertebrates, turns out to control body-axis elongation in mammals as well. When researchers increased Lin28a expression in mouse tail-bud cells, the animals developed strikingly more tail vertebrae and showed increased cell proliferation in the growing tail. Knocking out Lin28a did the opposite.³³ This pathway essentially controls the pool of progenitor cells available for continued growth, deciding when to keep self-renewing and when to stop. It is one of the clearest demonstrations that body size is not just about how fast cells grow but about how long the biological growth program stays switched on, a timing question as much as a rate question.